Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.
COVID-19
IGRA
IgG
SARS-CoV-2
immunoglobulin
interferon-gamma release assay
seroprevalence
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
06
2021
accepted:
25
08
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status.
Identifiants
pubmed: 34646805
doi: 10.3389/fpubh.2021.732787
pmc: PMC8502872
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
732787Informations de copyright
Copyright © 2021 Schiffner, Backhaus, Rimmele, Schulz, Möhlenkamp, Klemens, Zapf, Solbach and Mischnik.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nat Commun. 2021 Jul 19;12(1):4383
pubmed: 34282139
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
J Infect Dis. 2021 Jan 4;223(1):56-61
pubmed: 33128369
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
Signal Transduct Target Ther. 2020 Jul 2;5(1):112
pubmed: 32616709
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Lancet Healthy Longev. 2021 Jun;2(6):e362-e370
pubmed: 34104901
Scand J Work Environ Health. 2021 Jul 1;47(5):408-409
pubmed: 34003294
J Infect Dis. 2021 Jun 05;:
pubmed: 34089610
Infection. 2021 Aug;49(4):739-746
pubmed: 33689159
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Front Public Health. 2020 Sep 22;8:570543
pubmed: 33072707
Cell. 2020 Aug 20;182(4):843-854.e12
pubmed: 32673567
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Clin Infect Dis. 2020 Oct 09;:
pubmed: 33035306
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nat Rev Immunol. 2020 Jul;20(7):392-394
pubmed: 32514035
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176